150 results
Page 4 of 8
8-K
EX-99.1
6xjpkqphyf 6ha4b52io
29 Jan 21
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
7:03am
8-K
EX-99.1
kw2btcqt1qapd i07e
19 Jan 21
Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
7:03am
8-K
EX-99.1
xggw67ti8vqgc4 vas2
14 Jan 21
Interactions with FDA anticipated by mid-2021 to determine the BLA filing strategy for OTL-200
7:03am
8-K
EX-99.2
ugx7oike8qasl6fi43j
11 Jan 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
nro6bgp1fsl5 pm
11 Jan 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
o1u91
21 Dec 20
First gene therapy to receive full EU marketing authorization for eligible MLD patients
7:03am
8-K
ycshb2tthaez7d7
8 Dec 20
Other Events
7:03am
8-K
EX-99.1
11aqs
8 Dec 20
Other Events
7:03am
8-K
EX-99.1
dwcpd84roo
19 Nov 20
Other Events
7:03am
8-K
EX-99.1
ailu45ylrrgeoolvp
12 Nov 20
NOD2 mutation revealed as Crohn’s disease (CD) genetic target, associated with 7-10% of all CD cases in the U.S. and Europe
4:18pm
8-K
EX-99.1
nj94yzls
3 Nov 20
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results
7:03am
8-K
f2st kb49z0zqo
30 Oct 20
Other Events
4:40pm
8-K
EX-99.1
xuec2y1
16 Oct 20
Other Events
6:03am
8-K
EX-99.1
nyyts5t 9r
28 Sep 20
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
7:03am
8-K
EX-99.1
p0vswb3
1 Sep 20
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I
7:03am
8-K
EX-99.1
5mr48ea1s6bl81yk ry
6 Aug 20
Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
7:03am
8-K
EX-99.1
yt3ekjdad9am1a bf
20 Jul 20
Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
7:03am